While pharmacogenomics has been utilized in the field of psychiatry for over a decade, studies have shown that even with pharmacogenomics, 80% of individuals with treatment-resistant depression do not achieve remission within the first two months. Join us to discover interventions to improve these outcomes and deliver hope to your patients.

In this live seminar, come and learn about other modifiable genomic root causes of depression, ranging from gene variants that contribute to HPA axis and melatonin dysregulation, to variants that contribute to neurotransmitter synthesis, growth factors, and even the under-recognized, but important cause of BH4 deficiency.

You’ll discover how to map out the contributing root causes of depression, and specifically address each of the genomic variants that contribute to depression—via targeted, evidence-based interventions that incorporate diet, lifestyle, supplementation, and medications. You’ll also gain an in-depth on precision medicine application in daily practice, utilizing low-dose lithium for the treatment of anxiety and depression in relation to the CACNA1C gene. Lastly, we will review case studies of patients with these genes, and how lithium improved their symptoms.                                       

DATE & TIME: Saturday, November 8 from 11:00am-2:00pm ET.

SEMINAR FORMAT:  3 live lectures held via Zoom. (Registrants also gain access to all recordings with live seminar registration.)

THIS SEMINAR IS IDEAL FOR:  MDs and DOs (including psychiatrists, pediatricians, and family and general practice physicians), NDs and NMDs, nurses and nurse practitioners, psychologists, therapists, social workers, physician assistants, dietitians, and other health and mental health clinicians

REGISTRATION FEE:  $129

FACULTY: 
– Sharon Hausman-Cohen, MD, FAAFP, ABIHM
– Jennifer Reed, FNP, PMHNP
– James Greenbaltt, MD

What You’ll Learn

  • How genomics reveals root-cause vulnerabilities to depression
  • Beyond pharmacogenomics: the role of nutrigenomics, BDNF, BH4, MTHFR, HPA axis, and melatonin dysregulation in depression
  • Practical, precision-based strategies—including nutrition, lifestyle, supplementation, and medications—to target genomic variants
  • Emerging evidence on low-dose lithium in mood disorders, with case studies on gene variants such as CACNA1C and MTHFR
  • How to apply genomic insights in daily practice to personalize care and improve outcomes

Seminar Schedule

Introduction & Overview

11:00am-11:30am ET
James Greenblatt, MD

Join Dr. Greenblatt as he moderates the seminar, providing a foundational overview of genomics in psychiatry, the necessity of root-cause interventions for patients with depression, and the power of nutritional lithium to enhance outcomes.

Genomics of Depression – Mapping the Root Causes

11:30am-12:45pm ET
Sharon Hausman-Cohen, MD

In this talk, come learn about other modifiable genomic root causes of depression, ranging from gene variants that contribute to HPA axis and melatonin dysregulation to variants that contribute to neurotransmitter synthesis, growth factors, and even the under-recognized but important cause of BH4 deficiency. Most importantly, come and learn how to map out contributing root causes of depression and how to specifically address each of these genomic variants that contribute to depression in an integrative, evidence-based manner using diet, lifestyle, supplementation, and medications as targeted interventions.        

Low-Dose Lithium & Precision Psychiatry: Case-Based Insights

1:00pm-1:45pm ET
Jenny Reed, FNP, PMHNP

In this talk, Jennifer provides a foundational primer on precision medicine application in daily practice. She’ll review her recent, published research on low dose lithium for the treatment of anxiety and depression in relation to the CACNA1C gene. To help frame this research, she’ll also discuss patient case studies where this gene is present, and the application of nutritional lithium for symptom improvement. From there, she’ll explain how other genes contribute to depressive symptoms, including a key case study of a patient with the MTHRF genetic mutation, and how to apply targeted interventions.

Closing Panel with Open Q&A

1:45pm ET

Join all speakers for an open Q&A session to answer attendee questions, and review protocols, cases and the finer points of clinical application.



Join leading experts as they share evidence-based insights into the genetic underpinnings of depression, and practical, precision tools for treatment in this special, 3-hour seminar.

Meet the Seminar Speakers

Sharon Hausman-Cohen, MD, FAAFP, ABIHM

Dr. Sharon Hausman-Cohen is the Chief Medical Officer and co-founder of IntellxxDNA.  Dr. Hausman-Cohen has been in the field of integrative medicine for over 25 years and is the co-author of many publications and textbook chapters relating to using genomics to improve outcomes in environmental medicine, mental health, cognitive decline and autism. She is proud that IntellxxDNA is being used in IRB approved studies as well as by well-respected functional medicine trained physicians across the country. She and her co-founder developed IntellxxDNA as an answer to an unmet need in the medical community; the need for an accurate, evidence-based genomics tool geared at helping physicians practice true root cause medicine, whether the patient has mental health concerns, cardiometabolic concerns, cognitive decline or medical mysteries. Dr. Hausman-Cohen received both her master’s degree and medical degree from Harvard Medical School. In addition to supervising the research for IntellxxDNA she practices at Resilient Health in Austin.

Jennifer Reed, NP

Jennifer Reed, NP has worked in the medical profession for 35 years in a wide variety of specialties, including 20 years inpatient. She now has her own psychiatric practice in Kansas where she specializes in Precision Medicine. She spent many years working in cardiology as an RN and then became a nurse practitioner. She is double board certified in both Family Practice and Psychiatry. Her research on low dose lithium and the CACNA1C gene has been published in the Journal of the American Association of Nurse Practitioners (JAANP). Jenny trains other providers how to use Precision Medicine and lectures nationally on the subject. Her goal is to make pharmacogenetic testing the standard of care for all medicine and to show its utility in all specialties.

James Greenblatt, MD

Founder, Chief Medical Officer

James Greenblatt, MD, is is a pioneer in functional and integrative psychiatry and a board-certified child and adult psychiatrist who has been treating patients since 1988. He serves as an Assistant Clinical Professor of Psychiatry at Tufts University School of Medicine and Dartmouth’s Geisel School of Medicine. An internationally recognized speaker on nutritional interventions in mental health, Dr. Greenblatt has authored seven books, including the best-sellers Finally Focused and Answers to Anorexia, as well as his latest, Functional & Integrative Medicine for Antidepressant Withdrawal. In 2019, Dr. Greenblatt founded Psychiatry Redefined, the leading educational platform designed to transform psychiatric care through integrative, personalized and evidence-based approaches to treatment. Psychiatry Redefined bridges critical knowledge gaps for mental health professionals, providing a new hope for mental health care.